Biosynthetic rivalry of o-aminophenol-carboxylic acids initiates production of hemi-actinomycins in Streptomyces antibioticus by Crnovčić, Ivana et al.
RSC Advances
PAPER
Pu
bl
ish
ed
 o
n 
10
 D
ec
em
be
r 2
01
3.
 D
ow
nl
oa
de
d 
by
 T
U
 B
er
lin
 - 
U
ni
ve
rs
ita
et
sb
ib
l o
n 
25
/0
2/
20
16
 1
3:
23
:5
1.
 
View Article Online
View Journal  | View IssueTechnische Universita¨t Berlin, Institut fu¨r Ch
Berlin-Charlottenburg, Germany. E-mail: ull
25477
† Electronic supplementary information (
S2. See DOI: 10.1039/c3ra45661g
Cite this: RSC Adv., 2014, 4, 5065
Received 8th October 2013
Accepted 6th December 2013
DOI: 10.1039/c3ra45661g
www.rsc.org/advances
This journal is © The Royal Society of CBiosynthetic rivalry of o-aminophenol-carboxylic
acids initiates production of hemi-actinomycins in
Streptomyces antibioticus†
Ivana Crnovcˇic´, Siamak Semsary, Joachim Vater and Ullrich Keller*
Actinomycins consist of two pentapeptide lactone rings attached to 2-amino-4,6-dimethyl-3-oxo-
phenoxazine-1,9-dicarboxylic acid (actinocin). The actinocin moiety is formed through oxidative
condensation of two 3-hydroxy-4-methylanthranilic acid (4-MHA) pentapeptide lactones (actinomycin
halves) as the last step of actinomycin biosynthesis. We found that feeding of 4-MHA or its putative
biogenetic precursor 3-hydroxyanthranilic acid (3-HA) to Streptomyces antibioticus induced formation of
diﬀerent new compounds at the expense of actinomycins. These contain only one pentapeptide lactone
ring attached to the b-side of their phenoxazinone ring systems and are formed through premature
condensation of the externally added abundant 4-MHA or 3-HA with actinomycin halves. They were
termed hemi-actinomycins and C-demethyl-hemi-actinomycins, respectively, which diﬀer from each
other in the presence or absence of one or both methyl groups in their phenoxazinone moieties. 3-HA
also induces synthesis of various C-demethylactinomycins formed through condensation of actinomycin
halves in which 3-HA had been incorporated by the 4-MHA incorporating enzyme in lieu of 4-MHA.
3-HA was not converted to 4-MHA as revealed by its inability to stimulate synthesis of actinomycin or
hemi-actinomycin synthesis and thus remained a substrate analogue of 4-MHA rather than its precursor.
In contrast to S. antibioticus, actinomycin-producing streptomycetes such as Streptomyces chrysomallus
or Streptomyces parvulus do not form hemi-structured actinomycins when fed with 3-HA or 4-MHA.
They do not possess the enzyme phenoxazinone synthase (PHS) which in S. antibioticus is present and
most probably catalyses premature condensation of abundant 4-MHA or 3-HA with actinomycin halves.
Testing hemi-acinomycin IV for drug activity revealed that it intercalates into DNA and inhibits relaxation
and supertwisting of DNA by topoisomerase I and DNA-gyrase like actinomycin IV (D). Moreover, it has
inhibitory activity on growth of Bacillus subtilis.Introduction
Actinomycins are a family of chromopeptides with antineo-
plastic activity produced by various streptomycete strains.1 In
their structures, two pentapeptide lactone rings are attached to
a phenoxazinone dicarboxylic acid in amide linkages (Fig. 1).
Studies of actinomycin biosynthesis showed that the phenox-
azinone moiety (2-amino-4,6-dimethyl-3-oxo-phenoxazine-
1,9-dicarboxylic acid, called actinocin) is formed through
condensation of two 3-hydroxy-4-methyl-anthranilic acid
(4-MHA)-pentapeptide lactones (actinomycin halves) as last step
of actinomycin biosynthesis (Fig. 1).2,3 4-MHA is derived from
tryptophan in a pathway analogous to that of its demethyl-
homologue 3-hydroxyanthranilic acid (3-HA), an intermediateemie, Mu¨ller-Breslau Strasse 10, D-10623
rich.keller@tu-berlin.de; Tel: +49 30 314
ESI) available: Fig. S1–S7 and Tables S1,
hemistry 2014of nicotinic acid biosynthesis in all eukaryotes and a number of
bacteria.4 However, in contrast to 3-HA, 4-MHA formation is
restricted to streptomycete strains which produce actinomycins
and members of the diazepam group of natural compounds
such as anthramycin, sibiromycin or tomaymycin all of which
contain 4-MHA as building stone in their structures.5–7 The
reaction sequences leading from tryptophan to 4-MHA or 3-HA
diﬀer only in the presence of an additional methylation step
which introduces a methyl group into the benzene ring of
4-MHA (Fig. 1). In Streptomyces chrysomallus and Streptomyces
parvulus which produce actinomycin C and actinomycin D,
respectively, 3-hydroxykynurenine (3-HK) is methylated by the
3-HK-methyltransferases AcmI/L to give 3-hydroxy-4-methyl-
kynurenine (4-MHK) (Fig. 1, upper path).8 4-MHK is subse-
quently converted to 4-MHA by the hydroxykynureninase
AcmH.8,9 The same steps of 4-MHA synthesis were also found in
case of sibiromycin biosynthesis in Streptosporangium sibir-
icum.10 By contrast, in actinomycin X-producing Streptomyces
antibioticus, the methylation step appears to be catalyzed by a
methyltransferase whichmethylates 3-HA directly giving 4-MHARSC Adv., 2014, 4, 5065–5074 | 5065
Fig. 1 Formation of actinomycin D (IV) from actinomycin halves and formation pathways of 4-methyl-3-hydroxyanthranilic acid (4-MHA) in S.
chrysomallus via 4-methyl-3-hydroxykynurenine (MHK) or in S. antibioticus via 3-hydroxyanthranilic acid (3-HA). The asymmetric structure of
the phenoxazinone chromophore implies two diﬀerent sides (a or b) to which the peptide lactone rings can be attached. Moreover the
pentapeptide lactone rings can be diﬀerent (aniso-actinomycins) or be the same (iso-actinomycins) ACMS: actinomycin peptide synthetases,
Sar: N-methylglycine, MeVal: N-methyl-L-valine, AdoMet: S-adenosyl-L-methionine, 3-HK: 3-hydroxykynurenine.
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View Article Online(Fig. 1, lower path).11 Supporting evidence for this was the
earlier nding that 3-HA when added to S. antibioticus cultures
stimulated actinomycin synthesis apparently through enhanced
formation of 4-MHA.12,13 However, other in vivo incorporation
experiments with S. antibioticus showed that externally added
4-MHK stimulated actinomycin formation better than 3-HA
which suggested that the methylation step could well be at the
stage of 3-HK rather than of 3-HA.14
Surprisingly, we found recently that feeding 3-HA to cultures
of S. chrysomallus or S. parvulus had a stimulatory eﬀect on
actinomycin synthesis, too. However, analysis of the actino-
mycin mixtures formed revealed that the increase in product
formation exclusively referred to the additional formation of so-
called C-demethylactinomycins in which one or both 4-MHA
residues in the chromophore were replaced by 3-HA.15 In fact,
3-HA was not found to be converted to 4-MHA and instead was
incorporated directly into actinomycin half molecules by the
4-MHA-incorporating enzyme ACMSI which can accept 3-HA as
a structural homologue of 4-MHA.16 These data therefore stand
in stark contrast to the reported stimulating eﬀect of 3-HA on
actinomycin synthesis in S. antibioticus,12,13 because that same
4-MHA incorporating enzyme ACMSI is also present in S. anti-
bioticus.17 This prompted us to reinvestigate the eﬀects of 3-HA
and also 4-MHA on actinomycin biosynthesis in S. antibioticus.
It will be shown that feeding 3-HA and surprisingly also 4-MHA
to S. antibioticus cells suppresses actinomycin synthesis with
concomitant formation of new products formed by competitive
intervention of these highly reactive o-aminophenol-carboxylic
acids in diﬀerent steps of actinomycin synthesis.Materials and methods
Chemicals and radiochemicals
3-Hydroxyanthranilic acid (3-HA) and uorescence silica gel
60 F254 coated alumina sheets were from Merck (Darmstadt,
Germany). Actinomycin D was purchased from Applichem
(Darmstadt, Germany). Daunomycin was isolated from cultures5066 | RSC Adv., 2014, 4, 5065–5074of Streptomyces peucetius ATCC 29050 according to18 and puried
by HPLC. 3-Hydroxy-4-methylanthranilic acid (4-methyl-3-
hydroxyanthranilic acid, 4-MHA) was synthesized as described.19
[14C-methyl]-L-methionine (55 mCi per mmol), U-[14C]-L-valine
(260 mCi per mmol),U-[14C]-L-threonine (192 mCi per mmol), U-
[14C]-L-proline (252mCi per mmol), U-[14C]-L-glycine (105mCi per
mmol), U-[14C]-glutamic acid (238 mCi per mmol) and L-[5-3H]-
tryptophan (17.9 Ci per mmol) were from Amersham Bioscience
(Braunschweig, Germany). All other chemicals were of the high-
est purity commercially available. Cinnabarinic acid and actino-
cin were prepared from 3-HA and 4-MHA according to.20 The
compounds were conrmed by mass spectrometry showing [M +
H]+ ¼ 329 for actinocin and [M + H]+ ¼ 301 cinnabarinic acid.Strains and cultures
Strain Streptomyces antibioticus ATCC 14888 (IMRU 3720) was
from the American Type Culture Collection (Bethesda, Mary-
land, USA). It was maintained and grown in the glutamate-
mineral salts medium supplemented with 1% galactose plus
0.1% glucose as described.21 Incubation was at 30 C and 220
rpm in a New Brunswick G 25 shaker.Analytical methods
Solvent systems for thin layer chromatographic separation
of actinomycins and hemi-actinomycins was solvent
system I (ethylacetate–methanol–water–dimethylformamide,
100 : 5 : 5 : 2, by vol.). For separation of amino acid mixtures
solvent system II (butanol–acetic acid–water; 4 : 1 : 1, by vol.)
was used. HPLC separations of actinomycin mixtures were
performed on a prepacked EnCaPharm 100-RP18 column
(Molnar Institute, Berlin, Germany) isocratically with 60%
(by vol.) acetonitrile–water, 0.1% triuoroacetic acid (TFA) at a
ow rate of 1 ml min1 using a Pharmacia LKB (Pump 2248,
WWM 2141) HPLC system. For isocratic separation of hemi-
actinomycins, a 52% (by vol.) acetonitrile–water mixture con-
taining 0.1% TFA was used. Detection wavelength was 441 nm.This journal is © The Royal Society of Chemistry 2014
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View Article OnlineActinomycin contents of cultures were determined by extraction of
culture aliquots with ethylacetate and subsequent spectrophoto-
metric determination at 441 nm using authentic actinomycin D as
standard. Extracts containing radioactive actinomycins and
related compounds were determined by counting aliquots in a
Wallac 1409 liquid scintillation counter (Wallac, Turku, Finland).
Radioactive compounds on TLC plates were localized by radio-
scanning with a RITA radioscanner (Raytest, Straubenhardt,
Germany) or by autoradiography on Kodak BioMax MR Film. For
product analysis, the radioactive zones were scraped oﬀ the plates
and extracted with methanol. Aer evaporation to dryness, the
material was hydrolyzed in 250 ml 6 M HCl for 20 h at 105 C. The
hydrolysate was brought to dryness under reduced pressure and
nally dissolved in 50% ethanol, applied to silica gel plates and
chromatographed in solvent system II along with amino acid
standards. Radioactive amino acids were detected by radio-
scanning or autoradiography. Standards were visualized by
spraying with 0.1% ninhydrin in ethanol.
Short term radioincorporation experiments and micro-
preparative incubations of streptomycete mycelial
suspensions
Short term radioincorporation experiments were performed as
described in.15 3-HA or 4-MHA (100–250 mM) were added to
mycelial suspensions in the indicated concentrations together
with 1 mCi of 14C-labeled amino acid, i.e. either threonine,
valine, proline, glycine, methionine or 10 mCi 3H-labelled tryp-
tophan. Incubation was at 30 C and 220 rpm in a New Bruns-
wick G 25 Shaker (2.5 cm displacement) for up to 60 min.
Radioactive actinomycins and other neutral compounds were
extracted twice with 3 ml portions of ethylacetate. 200 ml from
the combined extracts were counted. The remainder was evap-
orated to dryness, dissolved in a minute amount of ethylacetate,
applied to silica TLC plates and separated by using solvent
system I. Micro-preparative incubations supplemented with
3-HA or 4-MHA and the diﬀerent amino acids of the actino-
mycin pentapeptide lactone rings were performed as
described.15 Aer shaking at 220 rpm and 30 C for up to 10 h
each ask was extracted three times with 2 ml portions of eth-
ylacetate. Combined extracts were evaporated to dryness and
separated by TLC. Individual bands were scraped oﬀ the plates,
and subjected to HPLC as described above. Product peaks of
interest were lyophilized and subjected to analysis by degrada-
tion and/or mass spectrometry.
Alkaline hydrogen peroxide oxidation of actinomycins
Alkaline oxidative cleavage of actinomycins, hemi-actinomycins,
C-demethyl-hemi-actinomycins or C-demethylactinomycins was
performed according to.22 To the actinomycin or hemi-actino-
mycin sample (20 to 100 mg) dissolved in 100 ml methanol were
added 500 ml of 3% hydrogen peroxide in 0.8 N NaOH. Aer
standing for 30 min at RT the mixture was acidied to pH 2.8
with diluted HCl (1.5 ml nal volume) and extracted three times
with 1.5 ml portions of ethylacetate. Combined extracts were
evaporated to dryness under reduced pressure, separated by
HPLC and subjected to HPLC-ESI mass spectrometry.This journal is © The Royal Society of Chemistry 2014DNA-binding assays
Electromobility shi assays (EMSA) were performed in a total
volume of 20 ml in Tris-buﬀer (50 mM) at pH 7.4. The incuba-
tions contained 60 ng ml1 pQE30 plasmid DNA (Qiagen,
Hilden, Germany) and 25 mg ml1 actinomycin D or hemi-acti-
nomycin IV. Controls contained no actinomycin or hemi-acti-
nomycin. Aer 60 minutes at 37 C the incubations were loaded
on a 1% agarose gel (12  8.4 mm thickness, TBE buﬀer) and
run at 6 V cm1. Aer this, bands were visualized by soaking the
gel in an ethidium bromide bath for 30 min and illumination
with ultraviolet light.Topoisomerase I and DNA-gyrase inhibition assay
Topoisomerase I assay was in a total volume of 20 ml top-
oisomerase I buﬀer and in the presence of 100 mg bovine serum
albumin (protocol by NEB, Frankfurt, Germany). It contained
60 ng pQE30 plasmid DNA (Qiagen, Hilden, Germany), 1 unit
topoisomerase I (NEB) and 0.5 mg ml1 actinomycin D or hemi-
actinomycin IV. The mixtures were allowed to stand at 37 C for 2
hours and aerwards were incubated for 15 minutes at 65 C for
inactivation of topoisomerase I. DNA-gyrase assay was in a total
volume of 20 ml DNA-gyrase buﬀer (protocol by NEB, Frankfurt,
Germany). The incubations contained 100 ng relaxed pUC19
plasmid DNA (NEB), 1 unit DNA-gyrase (NEB) and 10 mg ml1
actinomycin D, hemi-actinomycin IV or daunomycin. Themixtures
were allowed to stand at 37 C for 2 hours and aerwards were
incubated for 15 minutes at 65 C for inactivation of DNA-gyrase.
Electrophoretic separation was performed on a 1% agarose gel as
above. Staining of bands was with ethidium bromide.Inhibition assays
Disc diﬀusion assays for testing antimicrobial activity of hemi-
actinomycin and actinomycin against Bacillus subtilis ATCC
6633 were performed by standard procedures. Dened amounts
of compounds (dissolved in ethanol) were spotted on paper
discs (6 mm diameter, Schleicher and Schuell) and aer drying
were laid on a so top nutrient agar (Difco) inoculated with
0.1% (v/v) of an overnight culture of Bacillus subtilis ATCC 6633.
Aer incubation at 30 C over night diameters of inhibition
zones were determined.Mass spectrometric analysis
MALDI-TOFmass spectra were recorded using a Bruker Autoex
instrument equipped with a 337 nm nitrogen laser for desorp-
tion and ionization. 2 ml samples of HPLC-puried actinomycin
species were mixed with the same volume of matrix medium
(a saturated solution of a-cyano-4-hydroxycinnamic acid in 50%
aqueous acetonitrile containing 0.1% triuoroacetic acid),
spotted on the target, air dried and measured. Spectra were
recorded by positive ion detection in reector mode. The
acceleration and reector voltages were 19 and 20 kV in pulsed
ion extraction mode. A molecular gate of 350 Da improved the
measurement by ltering out most matrix ions. Monoisotopic
mass numbers were obtained. The structure of the new acti-
nomycins was investigated by post source decay (PSD)-MALDI-RSC Adv., 2014, 4, 5065–5074 | 5067
Fig. 2 Formation of C-demethylactinomycins and hemi-actinomy-
cins in S. antibioticus. Lane 1: separation of actinomycin mixture
formed in mycelial suspensions (with labeling by 14C-threonine). Lane
2: separation of actinomycins formed in the presence of 250 mM 3-HA.
Lane 3: separation of actinomycins formed in the presence of 250 mM
4-MHA. Separation was on silica thin-layer plates using solvent
system I. Time of exposure of the chromatogram to X-ray ﬁlm was 2
days. Acm: actinomycin. The abbreviations used to indicate the
diﬀerent new bands formed upon addition of 3-HA or 4-MHA are
explained in the text.
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View Article OnlineTOF mass spectrometry. The fragment spectra of C-demethy-
lactinomycins, hemi-actinomycins and C-demethyl-hemi-acti-
nomycins were compared with that of actinomycin as the
reference.
HPLC-ESI-MS experiments were recorded using an Exactive
ESI-Orbitrap-MS (Thermo Fisher Scientic GmbH, Bremen,
Germany) that was coupled to a HPLC 1200 Agilentsystem
(Agilent, Waldbronn, Germany). The scans were performed as
full scans (100–2000 m/z or 100–1000 m/z) and recorded by
positive and negative ion detection (2 scan events). HPLC was
performed using a 50  2 mm GRACE 3m Grom-Sil ODS-4 120
column (Grace Davison, Deereld, USA) with a ow rate of
0.2 ml min1. The mobile phase was A: water/formic acid (0.1%)
and B: acetonitrile/formic acid (0.1%). A linear gradient was
used from 5 to 100% B over 10 min, aer which it was switched
in 0.1 min to 5% B and remained there for 5 min.
Results and discussion
3-HA induces synthesis of novel actinomycins in Streptomyces
antibioticus
S. antibioticus IMRU 3720 produces actinomycins IV and V as
main components of the actinomycin X complex23 (Fig. S1†).
Actinomycin IV (synonymous with actinomycin D in Fig. 1) is an
iso-actinomycin possessing two identical pentapeptide lactone
rings each containing proline in the ‘proline’ site whereas
actinomycin V is an aniso-actinomycin with 4-oxoproline
instead of proline in its b-pentapeptide lactone ring. There is
also actinomycin I, a minor product, where the b-ring contains a
4-hydroxyproline residue in the ‘proline’-position23 (Fig S1†).
To examine the eﬀect of 3-HA on actinomycin synthesis in S.
antibioticus, washed mycelium was incubated in short-term
radioincorporation experiments with 14C-threonine and 250 mM
3-HA. Fig. 2 (lane 2) shows the separation of the ethylacetate-
extractable products which reveals that addition of 3-HA had led
to the formation of a variety of new labeled bands. Concomi-
tantly, the intensities of the actinomycin IV and V bands were
less intense when compared to the control experiment without
3-HA (Fig. 2, lane 1), indicating that the new compounds had
been formed at the expense of actinomycins. Recently obtained
knowledge of C-demethylactinomycins from S. chrysomallus
and S. parvulus suggested that the new compounds shortly
moving under the bands of actinomycin IV or V could be their
corresponding C-demethylactinomycins.15
These were the indicated double band (DIV and DDIV) under
the band of actinomycin IV (Rf  0.5) and two distinct bands
(DV(1) and DV(2)) under the band of actinomycin V (Rf  0.66).
However, there were also two further prominent bands with
lower Rfs, designated DHIV and DHV for which no counterpart
were seen to be formed in short term incubations of S. chrys-
omallus and S. parvulus15 and therefore most likely were no
C-demethylactinomycins.
Interestingly, the analysis of parallel incubations where cells
of S. antibioticus had been incubated with externally added 4-
MHA instead of 3-HA revealed that 4-MHA suppressed actino-
mycin synthesis also with concomitant formation of two new
compounds, HIV and HV, having coordinately higher Rf-values5068 | RSC Adv., 2014, 4, 5065–5074than the 3-HA-inducible ones. This suggested, that they were
the homologues of compounds DHIV and DHV and contained 4-
MHA instead of 3-HA. Radiochemical analysis of all new
compounds by acid hydrolysis and amino acid analysis revealed
that they contained 14C-threonine. Similarly, 14C-valine and
14C-N-methyl-L-valine were recovered from the compounds
when 14C-valine was used in parallel experiments to label these
bands (Fig. S2†). These data indicated that the 3-HA or 4-MHA-
inducible new compounds possessed the same peptide portions
as their corresponding actinomycins.
Larger non-labeled quantities of these compounds were
produced in micro-preparative incubations in the presence of
250 mM 3-HA (or 4-MHA) and 2 mM of the amino acids of the
pentapeptide lactone rings (see Materials and methods). The
separation of extracts from these incubations by preparative
TLC revealed an identical pattern of new bands formed in the
presence of the two aminophenol carboxylic acids like in the
short-term incubations with radiolabeled amino acids. All new
bands had a red-orange or brownish-orange colour indicating
that they contained a phenoxazinone chromophore (Fig. S3†).
Aer isolation from plates, each compound was puried further
by HPLC. Based on their spectral absorption at 441 nm and
taking the published extinction coeﬃcient for actinomycin D,
the typical total yield of new compounds from a micro-prepar-
ative incubation was between 50 and 150 mg (8–20 mg ml1).Identication of C-demethylactinomycins from S. antibioticus
For clarication of the various 3-HA- or 4-MHA-inducible
compounds we rst turned to the presumptive C-demethy-
lactinomycins. Mass spectrometry revealed that compoundThis journal is © The Royal Society of Chemistry 2014
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View Article OnlineDIV had a mass peak of [M + H]
+ ¼ 1242 and by comparison
with the earlier conrmed same compound from S. parvulus15
was identied as mono-(a)-C-demethylactinomycin IV
(D) (Fig. S1†). The accompanying compound DDIV showed a
mass peak [M + H]+ ¼ 1228 in agreement with the structure of
di-C-demethylactinomycin IV (Fig. S1†). Compounds DV(1)
and DV(2) surprisingly showed the same mass peak of
[M + H]+ ¼ 1255 which indicated for both a molecular weight
consistent with that of a mono-C-demethylactinomycin V for
which four isomeric structures are theoretically possible
(Fig. S1†).
To determine the location of the 3-HA residue in the phe-
noxazinone chromophores of these C-demethylactinomycins, in
vivo biosynthetic labeling experiments with 5-3H-tryptophan in
the presence of external 3-HA was performed (Fig. 3a). Taking
into account that the 5-3H-tryptophan only labels intracellularly
formed 4-MHA and that 3-HA remains unlabeled15,24 two
possibilities exist for the fate of the tritium in the 5-position of
labeled 4-MHA (Fig. 3b). When 4-MHA is on the a-side of the
phenoxazinone moiety, the label of radioactive 4-MHA is
retained, however, is lost when on the b-side (Fig. 3b). The data
in Fig. 3a (lane 2 and 3) show that 5-3H-tryptophan labels only
DV(2) whereas compound DV(1) and also DIV remain unlabeled.
This shows that in both DV(1) and DIV the 3-HA moiety was
incorporated into the a-side and thus are mono-(a)-C-Fig. 3 Regioselective incorporation of 3-HA into C-demethylactino-
mycin V(1) and V(2). (a) Lanes 1: 14C-threonine-labeled actinomycin IV
and V formed in mycelial suspension of S. antibioticus. Lane 2: 14C-
threonine-labeled actinomycins, C-demethylactinomycins and C-
demethyl-hemi-actinomycins formed in the presence of 3-HA. Lane
3: actinomycins, C-demethylactinomycins and C-demethyl-hemi-
actinomycins after labeling with 5-3H-tryptophan formed in the
presence of 3-HA. (b) Scheme of biosynthetic labeling of DV(1) and
DV(2) with 5-
3H-tryptophan. R: pentapeptide lactone rings.
This journal is © The Royal Society of Chemistry 2014demethylactinomycins. In contrast, DV(2) is a mono-(b)-C-
demethylactinomycin. Formation of a mono-(b)-C-demethy-
lactinomycin such as DV(2) has not been detected in S. parvulus
when fed with 3-HA. There, only mono-(a)-C-demethylactino-
mycin IV (DIV) was formed.15 However, the latter is an iso-acti-
nomycin with two identical pentapeptide lactone rings whereas
mono-C-demethylactinomycins V are aniso-actinomycins con-
taining two non-identical pentapeptide lactone rings. Appar-
ently, the presence of diﬀerent pentapeptide lactone rings has
inuence on the regiospecicity of the phenoxazinone forma-
tion reaction in S. antibioticus. It would be interesting, there-
fore, to know the location of the 4-oxo-proline containing
pentapeptide lactone ring in compounds DV(1) and DV(2). Due
to the limited amounts of available material, its localization has
not been achieved, yet.
3-HA and 4-MHA induce synthesis of hemi-actinomycins
The other two pairs of 3-HA- (DHIV and DHV) and 4-MHA-
inducible (HV and HIV) compounds on TLC-plates showed a
brownish-orange colour which distinguished them from the
red-orange coloured actinomycins (Fig. S3†). In methanolic
solution, their absorption maxima were diﬀerent from that of
actinomycin D (445 nm vs. 441 nm) and the compounds showed
a magenta-like colour in which they more resembled the
magenta colour of the actinomycin chromophore actinocin
(lmax ¼ 451 nm). We argued therefore, that they represented
phenoxazinones carrying only one pentapeptide lactone ring
and a free carboxy group which could be formed by the oxidative
condensation of abundant 4-MHA or 3-HA with actinomycin
halves (Fig. 4).
MALDI-TOF mass spectrometry of the anticipated hemi-
actinomycins (HIV and HV) and C-demethyl-hemi-actinomycins
(DHIV and DHV) conrmed this assumption. Compound HIV
displayed a mass peak [M + H]+ at m/z ¼ 792.5 in accordance
with the proposed structure as hemi-actinomycin IV (Fig. 5a).
Compound HV had a mass peak [M + H]
+ at m/z ¼ 806.6 in
agreement with the proposed structure of hemi-actinomycin V
(Fig. 5b). These conclusions were further corroborated by PSD-
MALDI-TOF mass spectrometric analysis for each compound
which revealed the same fragmentation pattern for the peptide
lactone rings as for actinomycin IV or V (Fig. S5 and Table S1†).
For the anticipated mono-C-demethyl-hemi-actinomycin DHIV aFig. 4 Structures of hemi-actinomycins formed in the presence of
excess 3-HA or 4-MHA. Schematic formation of hemi-structured
actinomycins in S. antibioticus in the presence of abundant 3-HA or 4-
MHA. R: methyl or H. In case of demethyl-hemi-actinomycins the R
substituent my be variable between the two possibilities.
RSC Adv., 2014, 4, 5065–5074 | 5069
Fig. 5 MALDI-TOF mass spectra of hemi-actinomycin IV (a) and V (b).
(a) Spectrum of hemi-actinomycin IV [M +H]+m/z¼ 792. (b) Spectrum
of hemi-actinomycin V [M + H]+ m/z ¼ 806.
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View Article Onlinemass peak [M + H]+ of m/z ¼ 778.5 veried its identity. Inter-
estingly, the compound was accompanied by small amounts of
a sister compound displaying an [M + H]+ of m/z 764.4, most
probably representing the di-demethyl derivative of hemi-acti-
nomycin IV (Fig S4†). Their assignment was again conrmed by
fragment analysis applying PSD-MALDI-TOF mass spectrometry
(Fig S5 and Table S1†). The mass data of representative frag-
ment ions are listed in Table S1† covering both fragments of the
peptide lactone ring and those which originate by elimination
of peptide portions of both demethylated species. Corre-
sponding fragments of the mono-C-demethyl- and di-C-
demethyl derivatives appeared at 14 and 28 mass units smaller
than those of hemi-actinomycin IV lacking one and two methyl
groups at the phenoxazinone chromophore, respectively. Their
names, masses and Rf values are listed in Table S2.†
To determine at which sides (a- or b-) of the C-demethyl-
hemi-actinomycins the 3-HA residues were located, in vivo
biosynthetic labeling of compounds DV(1) and DV(2) with 5-
3H-
tryptophan in the presence of external 3-HA was performed. The
TLC data in Fig. 3 (lower part of chromatogram) clearly show5070 | RSC Adv., 2014, 4, 5065–5074that though both mono-C-demethyl-hemi-actinomycins (DHIV
and DHV) were labeled with threonine (lane 2) no label derived
from 5-3H-tryptophan was detectable (lane 3). This indicated
that the tritium of 4-MHA was lost during phenoxazinone
formation which le no other possibility that in both
compounds the 3-HA residue was incorporated into the a-side.
Furthermore, to determine on which side of hemi-structured
actinomycins (and their demethyl-homologs) the pentapeptide
lactone rings are located we degraded hemi-actinomycin IV
(compound HIV) by treatment with alkaline hydrogenperoxide.
This cleaves actinomycins into two diﬀerent linear pentapep-
tide derivatives, one derived from the a-side with 7-methyl-
benzoxazalone-4-carboxylic acid at its amino terminus and the
other from the b-side carrying oxalic acid22 (Fig. S6†).
Fig. 6 shows the mass spectrum of products obtained by
NaOH/H2O2-cleavage of hemi-actinomycin IV (HIV) and – for
comparison – that of actinomycin IV. While in case of cleavage
of actinomycin IV the 7-methylbenzoxazalone-4-carbonyl- as
well as the oxalyl-pentapeptide were obtained (Fig. 6, upper
part) the cleavage of hemi-actinomycin exclusively delivered the
oxalyl-pentapeptide. This clearly proves that the single penta-
peptide lactone ring of the hemi-actinomycins is located to the
b-side of the phenoxazinone residue. Obviously, the condensa-
tion reaction between free 3-HA or free 4-MHA with 4-MHA-
(or 3-HA-) pentapeptide lactone rings was regiospecic. The
known chemistries of phenoxazinone formation catalysed by
e.g. peroxyl radicals25 or by enzymes such as tyrosinase (GriF)26
or phenoxazinone synthase (PHS)27 imply as rst step a 2-elec-
tron withdrawal from the o-aminophenol creating a quinone
imine which in turn is attacked by the amino group of a second
o-aminophenol (Fig. 7a). In case of unsymmetrical phenox-
azinones like grixazone from S. griseus, the rst step of
phenoxazinone condensation is the oxidation of 2-(N-ace-
tylcysteaminyl)-3-amino-4-hydroxybenzaldehyde (2-NAC-3,4-
AHBAL) to the corresponding quinone imine which in turn
reacts with 3,4-AHBAL to grixazone with incorporation of the
bulkier 2-NAC-3,4-AHBAL to the b-side of the phenoxazinone
(Fig. 7b). The nal phenoxazinones are then formed in two
further 2-electron removing steps (omitted in Fig. 7b). The
regiochemistry of grixazone therefore reects in a way the
formation of the b-oriented hemi-actinomycins suggesting that
the aminophenol carrying a larger substituent ortho to the
amino group is faster converted to the quinone imine than the
non-substituted one. Similar ndings have been reported on
the formation of diﬀerent unsymmetrical phenoxazinones cat-
alysed by laccase.28
Apparently, in S. antibioticus the formation of hemi-actino-
mycins is similarly regiospecic directing the actinomycin half
molecule to the b-side of the phenoxazinone nucleus although
both 3-HA or 4-MHA – when externally added – are in excess over
the concentrations of actinomycin halves in the cells. Neverthe-
less, during the incubations the symmetrical chromophores
cinnabarinic acid or actinocin, respectively, were produced in
parallel and in appreciable amounts as revealed by the presence
of their bands of Rf  0.15 and 0.19 both showing a magenta
colour on TLC plates (Fig. S3†). The identity of both compounds
was conrmed by co-chromatography with authentic references.This journal is © The Royal Society of Chemistry 2014
Fig. 6 Mass spectrometric analysis of alkaline hydrogen peroxide digested actinomycin IV and hemi-actinomycin IV. The digest was separated
by HPLC and factions containing fragments of cleavage analysed by mass spectrometry. Upper panel: digest of 100 mg actinomycin IV contains
both fragments of the a- and b-side. Lower panel: digest of 45 mg hemi-actinomycin IV contains only the peptide fragment derived from the
b-side.
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View Article OnlineIn contrast, neither formation of cinnabarinic acid or actinocin
was detectable in parallel incubations of mycelial suspensions of
S. chrysomallus or S. parvulus with 3-HA or 4-MHA nor was
formation of hemi-actinomycins observed.15 It is known that
S. antibioticus possesses phenoxazinone synthase (PHS) but that
this enzyme is missing in S. chrysomallus and S. parvulus.29 The
presence of PHS in S. antibioticus was directly visible during the
incubations with 3-HA or even stronger with 4-MHA because
mycelial suspensions turned deeply red when incubated with
these compounds. In contrast, the mycelial suspensions of
S. chrysomallus or S. parvulus in the same conditions developed a
slight reddish tone only. We checked PHS activity in protein
extracts from S. antibioticus. These extracts catalysed conversion
of 4-MHA to actinocin or 3-HA to cinnabarinic acid. In contrast,This journal is © The Royal Society of Chemistry 2014protein extracts from S. chrysomallus or S. parvulus did not
possess such enzyme activity.
We also considered the possibility that the hemi-actinomy-
cins and demethyl-hemi-actinomycins were formed from pre-
formed actinocin or demethyl-cinnabarinic acid to which the
peptide chain of actinomycin had been added instead by
condensation of 4-MHA or 3-HA with actinomycin halves.
However, the fact that in the presence of 3-HA mono-a-C-
demethyl-hemi-actinomycin IV (DHIV) was always formed in
excess over the di-C-demethyl-hemi-actinomycin IV clearly
excludes this possibility. Since in incubations with 3-HA
formation of cinnabarinic acid is observed in abundance
(Fig. S3†) one had to expect formation of excess di-C-demethyl-
hemi-actinomycins which, however, was not observed. ItRSC Adv., 2014, 4, 5065–5074 | 5071
Fig. 7 Schemes of enzymatic phenoxazinone formations. (a) Mech-
anism of PHS from Streptomyces antibioticus in the oxidation of
3-HA30 (b) mechanism of tyrosinase GriF from Streptomyces griseus
catalysing condensation of 3-amino-4-hydroxybenzaldehyde with
2-N-acetyl-cysteinyl-3-amino-4-hydroxybenzaldehyde in the
formation of grixazone.26
Fig. 8 Hemi-actinomycins bind to DNA and inhibit topoisomerase I
and DNA-gyrase. (a) Electromobility shift assay with plasmid pQE30
(ccc form). 1 no addition, 2 with hemi-actinomycin, 3 with actino-
mycin. (b) Relaxation of plasmid pQE30 (ccc form) by topoisomerase. 1
no addition, 2 with topoisomerase I, 3 with topoisomerase I and hemi-
actinomycin, 4 with topoisomerase I and actinomycin. (c) Supercoiling
of plasmid pUC19 (relaxed form) by DNA gyrase. 1 plasmid only, 2 with
gyrase (4 h incubation), 3 with gyrase (8 h incubation), 4 with gyrase
and daunomycin (2h incubation), 5 with gyrase (2 h incubation), 6 with
gyrase and hemi-actinomycin, 7 with gyrase and actinomycin, for
details see Materials and methods.
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View Article Onlinetherefore is unlikely that preformed phenoxazinone chromo-
phores are precursors of C-demethyl-hemi-actinomycins or
hemi-actinomycins. Thus, the most conceivable route of
formation of demethyl-hemi-actinomycins or hemi-actinomy-
cins is via the condensation of 3-HA or 4-MHA with preformed
actinomycin halves.
Drug activity of hemi-actinomycin as DNA-intercalator
Hemi-actinomycin IV was tested for its ability to bind to DNA.
Fig. 8a shows electromobility shis with plasmid DNA in the
presence and absence of hemi-actinomycin IV or actinomycin
IV. There is a clear shi of plasmid DNA to higher molecular
weight in the presence of hemi-actinomycin IV as well as of
actinomycin IV. In case of the latter the shi was higher in
accordance with the higher molecular weight of actinomycin IV
compared with hemi-actinomycin IV (1255 vs. 792). The fact that
hemi-actinomycin has a negative charge at neutral pH may also
be a reason. In any case, this nding suggests that hemi-acti-
nomycin IV intercalates into DNA like actinomycin IV. It is
known that the intercalation of actinomycin to DNA is through
the major groove but that it is stabilized by the two pentapep-
tide lactone rings extending perpendicularly to the chromo-
phore into both directions of the minor groove.31 The data
shown here indicate that one ring alone is suﬃcient for binding
of hemi-actinomycin to the minor groove of DNA. In contrast,
incubating plasmid DNA with the actinomycin chromophore
actinocin did not result in shis.
Actinomycin is a known inhibitor of topoisomerase I pre-
venting relaxation of cccDNA by stabilizing the open complex5072 | RSC Adv., 2014, 4, 5065–5074between DNA and the enzyme.32 Fig. 8b shows that top-
oisomerase I relaxes cccDNA with formation of a ladder of
diﬀerent conformers. As to be expected, in the presence of
actinomycin IV no ladder is formed and the plasmid DNA
remains ccc. Similarly, also in the presence of hemi-actinomycin
IV no ladder is formed.
We were also interested to see whether hemi-actinomycin
inhibited DNA gyrase. Relatively little is known about the
inhibiting eﬀect of actinomycin on DNA gyrase. Since dauno-
mycin which like actinomycin is a DNA-intercalating drug and
strongly inhibits DNA gyrase we expected that actinomycin and
eventually hemi-actinomycin would inhibit gyrase also.33 Fig. 8c
shows that actinomycin inhibits supercoiling of relaxed DNA by
DNA gyrase. Instead of forming the ladder consisting of
diﬀerent topoisomers, the enzyme was inhibited by actino-
mycin and the DNA stayed relaxed. In agreement with the data
obtained with topoisomerase I, hemi-actinomycin IV also
inhibited DNA gyrase which strongly indicates that hemi-acti-
nomycin exerted its eﬀect through intercalation into DNA
(Fig. 8).
Hemi-actinomycin IV was tested for antimicrobial activity
against Bacillus subtillis. Plate diﬀusion tests showed in vivo
inhibitory activity of hemi-actinomycin IV in accordance with the
inhibitory action of hemi-actinomycin against topoisomerase IThis journal is © The Royal Society of Chemistry 2014
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View Article Onlineand DNA gyrase. Semiquantitative determination revealed
that hemi-actinomycin was about 15fold less active than
actinomycin (as estimated from diameter of inhibition zones
at diﬀerent concentrations of hemi-actinomycin IV and acti-
nomycin IV) (Fig S7†).Natural occurrence of hemi-actinomycins
It is known that the highly reactive 4-MHA is present in the cell
of actinomycin-producing streptomycetes at very low concen-
tration.16,19 This may be necessary to avoid premature conden-
sation of 4-MHAmolecules with each other yielding actinocin or
as we know now with actinomycin halves leading to hemi-acti-
nomycins. Nevertheless, we expected that small amounts of
4-MHA could accumulate during longer cultivations of S. anti-
bioticus and react with actinomycin halves resulting in forma-
tion of hemi-actinomycins. This expectation was based on our
earlier observations that long-incubated cultures of S. chrys-
omallus or S. parvulus contain small amounts of C-demethy-
lactinomycins formed from traces of 3-HA that were
continuously formed from premature cleavage of 3-hydrox-
ykynurenine that escaped the 4-MHA pathway (Fig. 1).15 Mass
spectrometric analysis of extracts from such 1 week old cultures
of S. antibioticus in fact revealed the presence of trace amounts
of both hemi-actinomycin V and IV. However, the amounts of
these compounds were too low to analyse their regiochemistry.Conclusions
That feeding 3-HA or 4-MHA to actinomycin-producing S. anti-
bioticus gave rise to the formation of b-hemi-actinomycins and
b-C-demethyl-hemi-actinomycins, respectively, with suppression
of actinomycin shows that these structurally similar amino-
phenolic carboxylic acids can intervene in the phenoxazinone
forming reaction by prematurely condensing with actinomycin
halves. The data also show 3-HA is not precursor of 4-MHA
because – apart from its role as precursor of demethylactinomy-
cin – 3-HA induces synthesis of mono-C-demethyl-hemi-actino-
mycins and to lesser extent of di-C-demethyl-hemi-actinomycins
but not of hemi-actinomycins. Thus, 3-HA plays only a role as a
substrate analogue of 4-MHA in the assembly reaction of acti-
nomycin halves or during phenoxazinone formation snatching
away actinomycin halves before they condense with another
actinomycin half giving actinomycin or demethylactinomycin.
Our data, therefore, stand in agreement with previous ndings of
Perlman and coworkers who suggested that 4-MHA is derived
from 4-methyl-3-hydroxykynurenine (4-MHK) rather than from 3-
HA.14Wehave recently cloned the S. antibioticus orthologue of the
gene acmL encoding 3-hydroxykynurenine (3-HK) methyl-
transferase from S. chrysomallus (Crnovcic and Keller, unpub-
lished). This gene was designated acmSaL (Acc. no. KF860152). Its
translated gene sequence has 85% identity to AcmL and the sizes
of the two proteins are the same. The presence of this gene is a
further hint for the possible involvement of 4-MHK in 4-MHA
biosynthesis of S. antibioticus.
Previous biochemical studies on phenoxazinone formation
in actinomycin-producing streptomycetes revealed the presenceThis journal is © The Royal Society of Chemistry 2014of phenoxazinone synthase (PHS) in S. antibioticus but not in S.
chrysomallus30 The fact that S. antibioticus but not S. chrys-
omallus (or S. parvulus) produces hemi-actinomycins and
demethyl-hemi-actinomycins suggests that phenoxazinone syn-
thase (PHS) is responsible for synthesis of these novel
compounds. PHS has broad substrate specicity by which it is
capable to dimerize various structurally diﬀerent o-amino-
phenols into the corresponding phenoxazinones.1 Although
PHS was shown to be dispensable for actinomycin synthesis in
S. antibioticus,34 the data shown here indicate that the presence
of this enzyme is correlated to the reaction of abundant 3-HA or
4-MHA with actinomycin halves in contrast to the situation
found in S. chrysomallus and S. parvulus. Their phenoxazinone
formation is most likely spontaneous3,16 and the cellular loca-
tion of the reaction must be compartmentalized to prevent its
overow with free 4-MHA or 3-HA.15 The involvement of PHS in
hemi-actinomycin synthesis in S. antibioticus would be the rst
indication of the in vivo involvement of PHS in phenoxazinone
formation in S. antibioticus and shows that this enzyme can
assist in the formation of actinomycins. The real role of PHS is
still unknown and it may have a protective role in cellular
metabolism by neutralizing excess 4-MHA or other o-amino-
phenols which otherwise are toxic to the cell.35 Notwithstanding
this, formation of hemi-actinomycins may not be a too severe
handicap to S. antibioticus since these compounds still exert
antimicrobial activity albeit less strongly than actinomycin.Acknowledgements
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